Do lisinopril and atorvastatin cause erectile dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lisinopril and Atorvastatin Relationship to Erectile Dysfunction

Lisinopril (an ACE inhibitor) is NOT commonly associated with erectile dysfunction, while atorvastatin shows conflicting evidence with some studies suggesting it may worsen ED, particularly at higher doses.

Lisinopril and Erectile Dysfunction

ACE inhibitors like lisinopril have a low risk of causing erectile dysfunction compared to older antihypertensive agents. According to the American Association of Clinical Endocrinologists guidelines, while antihypertensive medications can cause ED through drug-specific effects or by decreasing blood pressure (thereby reducing intracavernosal penile pressure), "dysfunction with angiotensin-converting enzyme inhibitors or calcium channel blockers is less common" compared to older agents like beta-blockers, reserpine, guanethidine, and hydralazine 1.

The FDA drug label for lisinopril lists "impotence" under urogenital adverse reactions, but this occurs at rates similar to or only slightly higher than placebo in clinical trials 2. The 2018 ACC/AHA hypertension guidelines acknowledge that some antihypertensive drugs can negatively affect erectile function, but emphasize that the availability of phosphodiesterase-5 inhibitors "makes drug class distinctions for erectile dysfunction less relevant" 3.

Key Clinical Point for Lisinopril:

  • If a patient on lisinopril develops ED, consider that hypertension itself is a major risk factor for ED due to microvascular and neurovascular changes 1
  • The underlying cardiovascular disease is likely more contributory than the ACE inhibitor
  • Do not discontinue effective antihypertensive therapy without considering PDE-5 inhibitor treatment first

Atorvastatin and Erectile Dysfunction

The evidence for atorvastatin is contradictory and dose-dependent, with higher doses potentially worsening ED while lower doses may improve it in some patients.

The Canadian statin guidelines note "conflicting data are available regarding an association of statin use with erectile dysfunction," acknowledging that overlapping risk factors between ED and cardiovascular pathology complicate interpretation 4. However, recent evidence suggests concern:

  • A 2024 pharmacovigilance study found a significant association between atorvastatin and ED with an odds ratio of 3.71 and Mendelian randomization supporting causality (OR = 23.91, p = 0.02) 5

  • A 2014 comparative study showed atorvastatin significantly lowered IIEF scores (p = 0.019) while rosuvastatin showed no effect on ED 6

  • Animal studies demonstrated atorvastatin reduced intracavernosal pressure and minimally decreased testosterone levels 7

  • A 2014 Russian study found dose-dependent effects: higher atorvastatin doses (40mg) were associated with 8% decrease in erectile function and 10% decrease in androgen status 8

Conversely, some evidence suggests benefit:

  • A 2022 meta-analysis of RCTs found atorvastatin improved IIEF-5 scores by 4.53 points compared to placebo (95% CI 3.28-5.79) 9

  • The Canadian guidelines note statins "might be protective against ED, secondary to their contribution to an overall enhanced endothelial function" 4

Clinical Algorithm for Atorvastatin:

  1. For patients without ED starting atorvastatin: Use the lowest effective dose for lipid control; monitor for sexual dysfunction symptoms

  2. For patients developing ED on atorvastatin:

    • Consider switching to rosuvastatin, which showed no ED effect in comparative studies 6
    • If atorvastatin must be continued, reduce to lowest effective dose (10-20mg rather than 40mg) 8
    • Add PDE-5 inhibitor therapy, which can be safely co-administered 4
  3. For patients with pre-existing ED and dyslipidemia: Consider rosuvastatin as first-line statin or use atorvastatin ≤20mg with concurrent PDE-5 inhibitor 6, 10

Critical Caveats

The underlying cardiovascular disease and metabolic conditions requiring these medications are themselves major causes of ED through endothelial dysfunction, atherosclerosis, and microvascular disease 1, 3. Medications account for approximately 25% of ED cases, but multiple medications have additive effects, particularly in older men with diabetes or hypertension who have underlying microvascular disease 1.

Never discontinue cardiovascular protective therapy without addressing ED through appropriate treatment (PDE-5 inhibitors as first-line per ACP guidelines 11), as the cardiovascular benefits far outweigh potential sexual side effects, and effective ED treatment is available.

References

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

Related Questions

Can the listed medications—losartan 50 mg at noon and midnight, amlodipine besylate 5 mg at noon, bisoprolol hemifumarate 1.25 mg at noon, low‑dose aspirin (acetylsalicylic acid) 100 mg at night, rosuvastatin calcium 20 mg at night, and ezetimibe 10 mg at night—cause erectile dysfunction or decreased libido?
In a patient with controlled diabetes mellitus, hypertension, and hyperlipidemia who is taking amlodipine 10 mg daily, benazepril 20 mg daily, atorvastatin 20 mg daily, and ezetimibe 10 mg daily, what is the most appropriate first‑line therapy for erectile dysfunction, what parameters should be monitored, and is a specialist referral required?
Should grapefruit be avoided while taking tadalafil or atorvastatin?
What antibiotic regimen should be used to cover MRSA, anaerobes, and gram‑negative organisms in a patient who is allergic to vancomycin?
How do Kegel (pelvic‑floor) exercises help when the internal anal sphincter (IAS), which is smooth muscle, cannot be strengthened?
When should vitamin D supplementation be initiated, and what are the contraindications?
Which test—endoanal ultrasound or anorectal manometry—demonstrates internal anal sphincter (IAS) or external anal sphincter (EAS) defects?
How frequently should colonoscopies be performed?
A patient with severe nocturnal leg spasms, whose neurologist suspects Parkinson disease (PD) and who suspects restless legs syndrome (RLS), what is the appropriate next step in evaluation and management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.